Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

156
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
156
Altered States of Awareness01:06

Altered States of Awareness

147
Altered states of consciousness represent significant deviations from one's normal mental state. These deviations can range from subtle changes in awareness to profound transformations in perception, thought processes, and sensory experiences. Altered states of consciousness can be triggered by various factors, including drug use, meditation, hypnosis, illness, or even intense fatigue.
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
147
CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

124
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
124
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Radical Halogenation: Stereochemistry01:33

Radical Halogenation: Stereochemistry

3.7K
Stereochemistry is the study of the different spatial arrangements of atoms in a given molecule. The stereochemistry of radical halogenations can be understood from three different situations:
Halogenation to form a new chiral center:
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Ste20 kinase TAOK3 restrains Rac-driven cytoskeletal-mitochondrial coupling to preserve naive CD8<sup>+</sup> T cell homeostasis and activation.

Frontiers in immunology·2026
Same author

Assessing the capability of large language models in answering pediatric critical care board-style questions.

Scientific reports·2026
Same author

<i>Trans</i>-eQTLs reveal the architecture of human gene regulatory networks.

medRxiv : the preprint server for health sciences·2026
Same author

Translation of surface electromyography into a clinically applicable objective bulbar assessment tool to improve measurement-based care in amyotrophic laterals sclerosis.

Frontiers in neuroscience·2026
Same author

<i>The Safer Spaces Project</i>: a whole of community systems approach to co-designing and implementing a 'Safer Spaces' model of primary healthcare for LGBTQ+ young people in Western Victoria - a protocol for a mixed-methods study.

BMJ open·2026
Same author

ALS untangled #83: clenbuterol.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

An open-label Phase 2a study of fasudil in amyotrophic lateral sclerosis: safety and exploratory endpoints.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Noninvasive assessment of cardiovascular autonomic reflexes in amyotrophic lateral sclerosis: a systematic review.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

The connection between unproven stem cell-based interventions and complementary and alternative medicine in crowdfunding for Amyotrophic Lateral Sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Thinning of the oral motor cortex is linked to impaired speech in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Brain activity in an end-stage ALS patient suggests the presence of an unresponsive wakefulness syndrome.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
Same journal

Whole-body muscle MRI improves diagnostic certainty in amyotrophic lateral sclerosis.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2025

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

8.8K

ALSUntangled #77: Psilocybin.

Bhavya Bakshi1, Sandeep Yerraguntla1, Carmel Armon2

  • 1Medical School, Medical College of Georgia at Augusta University, Augusta, GA, USA.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|December 22, 2024
PubMed
Summary
This summary is machine-generated.

Psilocybin, a psychedelic, shows potential for slowing ALS progression due to its neuroprotective mechanisms. However, current research is lacking, and risks of side effects mean its use is not yet supported for treating ALS.

Keywords:
Psilocybininflammationneurogenesispsychedelics

More Related Videos

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.3K
Examining Monosynaptic Connections in Drosophila Using Tetrodotoxin Resistant Sodium Channels
09:55

Examining Monosynaptic Connections in Drosophila Using Tetrodotoxin Resistant Sodium Channels

Published on: February 14, 2018

9.9K

Related Experiment Videos

Last Updated: Jun 4, 2025

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

8.8K
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

7.3K
Examining Monosynaptic Connections in Drosophila Using Tetrodotoxin Resistant Sodium Channels
09:55

Examining Monosynaptic Connections in Drosophila Using Tetrodotoxin Resistant Sodium Channels

Published on: February 14, 2018

9.9K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Amyotrophic Lateral Sclerosis (ALS) Research

Background:

  • Patient interest in alternate and off-label treatments for ALS is growing.
  • Psilocybin, a psychedelic compound from mushrooms, is being explored for therapeutic potential.

Purpose of the Study:

  • To review the potential of psilocybin as a disease-modifying therapy for Amyotrophic Lateral Sclerosis (ALS).
  • To assess the current evidence and risks associated with psilocybin use in the context of ALS.

Main Methods:

  • Literature review of psilocybin's properties and potential effects on neurogenesis and inflammation.
  • Assessment of existing pre-clinical models, case reports, and clinical trials related to psilocybin and ALS.

Main Results:

  • Psilocybin can cross the blood-brain barrier and has plausible mechanisms for impacting neurogenesis and inflammation.
  • There are currently no pre-clinical ALS models, case reports, or trials evaluating psilocybin for ALS disease modification.
  • High risk of psychological side effects (hallucinations) and physical harm exists, dependent on dosage.

Conclusions:

  • The use of psilocybin is not currently supported as a means to slow ALS progression due to insufficient evidence and potential risks.
  • Further research is needed to establish the safety and efficacy of psilocybin for ALS treatment.